Kazuhiro Sase

Cardio-Oncology. Clinical Pharmacology and Regulatory Science. US-Japan HBD. JOCS. JSTAR. Sarcoma Awareness.

[Kazuhiro Sase @ksase]

Just published.
#VIEWPOINT on #ESC #CPG
Sase K, Mukai M, Fujiwara Y, et al. Clinical Practice Guidelines in Cardio-Oncology: A Sea of Opportunity. J Am Coll Cardiol #CardioOnc
https://t.co/pGGyHEXhZu
@JACCjournals @ACCintouch @ESCardio @ICOSociety @jocs_promotion @JCIRC_IPR

[Mike Fradley, MD @Dr_Mike_Fradley]

A little late in posting but honored to represent @ICOSociety and @PennMDForum at China Valve and the Synergy in Cardio-Onocology symposium. Impressed with the commitment to #cardioonc across China and left with stronger bonds for future collaborations 🤝

[Eric Topol @EricTopol]

Big progress vs cancer, folks.
The kind of event curves from randomized trials that we've not seen before for a couple of the most deadly cancers. Congrats to the oncology research community for getting these trial done. #ASCO26, @ASCO

[Avirup Guha, MBBS, MPH, FICOS, FACC, FAHA, FESC @avirupguha]

Cardiovascular prevention in #prostatecancer needs tools that actually fit oncology workflows.
We built + externally validated PC-specific risk scores for ASCVD, heart failure, and CVD using variables already available in cancer clinics. Introducing the GUHA-STABELLINI score

[International Cardio-Oncology Society @ICOSociety]

Our members are having a great show at #ASCO26, sharing the latest #cardiooncology insights with the broader @ASCO community.

Members - share your favorite highlights with us!

📸@Dr_Mike_Fradley and @sdent_cardioonc

#cardioonc #cardiology #oncology

[Mike Fradley, MD @Dr_Mike_Fradley]

Honored to present real world data evaluating CV outcomes and health care utilization in patients with CLL treated with BTK inhibitors. 🎯Afib is common and leads to ⬆️ adverse outcomes and stress on the health care system. 🔑early RF modification and treatment of #afib

[Parmita Mishra @parmita]

RAS finally getting drugged is one of the great stories in modern biology, and almost nobody outside oncology understands why it's such a big deal.

YOU'LL LEARN SOMETHING AWESOME TODAY.

i am going to keep this as understandable (and simple) as i can.

OPEN THE THREAD.

🧵

[Erman Akkus @Erman_Akkus]

Propensity Score–Matched External Controls in Rare Disease Trials: A Promising Tool Requiring Rigorous Validation | Journal of Clinical Oncology https://t.co/LPgUdF3xgw

[N.Sakurai@CANSOL @survivorship_JP]

過去、何回かこのシーンに同席したことがあります。皮膚がん免疫cp、destiny試験など。でも今回は膵がんです。膵がん。RASは膵がんの9割がもってますから、本当に希望。

[Massimiliano Camilli @Massimi78530343]

#COOL group of the @ESCardioOnco is a vibrant, young community for #CardioOncology leaders of tomorrow⏭️ Join our sessions at #ESCCardioOnc2026🇦🇹

[Crémieux @cremieuxrecueil]

This is actually insane.

97% of people taking the standard of care for metastatic solid tumor got worse by seven years.

But with lorlatinib, that number was only 45% in the same time!

This is an ENORMOUS jump in the quality of cancer care.

[NEJM @NEJM]

Presented at #ASCO26:

Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: https://t.co/xwLWBZYRzq

@ASCO

[C. Michael Gibson MD @CMichaelGibson]

GREAT NEWS !

Ground breaking improvement in survival in patients with #pancreatic cancer with #Daraxonrasib which should now be available ! https://t.co/MCuL6Zk8km

[International Cardio-Oncology Society @ICOSociety]

Thanks to the authors:
@sdent_cardioonc , @michellebnadler, @BlaesAnneMD, Ahamed Iqbal, Hannah Naa Gogwe Ayettey, Jose Alvarez‑Cardona, @alexchan928, Eng‑Siew Koh, @DrRaulCordoba, @MridulaGeorgeMD, Naa Adorkor Aryeetey, @erin_howden, @ksase, Nida Latif, Aya F. Ozaki, @semple_cherith, @drtarsh, @Neil_Iyengar, @hoperugo, @bogda_koczwara

[International Cardio-Oncology Society @ICOSociety]

📰 HOT OFF THE PRESS: Our joint statement with @CancerCareMASCC Prevention and management of #cardiovasculardisease in adults with #cancer has been published in Supportive Care in Cancer.

Read the statement: https://t.co/5EMDfqkuJg

#cardiooncology #cvd #MedTwitter #cancercare

[International Cardio-Oncology Society @ICOSociety]

🎟️ Early bird tickets for #GCOS26 are open – but only until June 30!

Lock in the best rate before it's gone. Don't miss the #CardioOncology event of the year.

Register now: https://t.co/B7U3k7t7RL

#cardioonc #Cardiology #HealthcareConference #MedTwitter

[ESC Council of Cardio-Oncology Chairperson @ESCardioOnco]

Why join #ESCardioOnco26 in Vienna?
A true 360° view of #cardiooncology, cutting-edge science + real-world care.
- Practical, case-based sessions
- Tracks for all levels
- Focus on prevention & survivorship

⏳ Early reg ends 22 April
Register now: https://t.co/P0o8QV30NH

[Yonemoto N @nyonenyone]

https://t.co/VolN4qGxjn

[JACC Journals @JACCJournals]

Biomarkers are everywhere—but how many actually matter? 🧪 Most fail when it counts. This #JACC paper separates hype from reality: https://t.co/rb6kvKXB1Z

@JavedButler1 @LauraDemichieli

[Javid Moslehi @CardioOncology]

Our vision for the cardio-immunology program at UCSF! We will be hiring new post-doctoral fellows and physicians in this space. Stay tuned for more information! @UCSFCardiology @immunox

[Kazuhiro Sase @ksase]

@masayomasayo PMDAにもワシントン支局ができました。医療機器では審査部や安全部だけでなく国際部の活躍によりFDAから頼りにされ、日米を軸に国際規制調和の方向性が安定した、という経緯もあります。他のモダリティでも、是非！